Cargando…
The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa
INTRODUCTION: Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the res...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255965/ https://www.ncbi.nlm.nih.gov/pubmed/32523647 http://dx.doi.org/10.11604/pamj.2020.35.69.21018 |
_version_ | 1783539818213408768 |
---|---|
author | Alain, Chabo Byaene Antoine, Lufimbo Katawandja Bizette, Bizeti Nsangu Dahlia, Pambu Dophie, Tshibuela Beya Jérémie, Muwonga Masidi Donatien, Kayembe Nzongola-Nkasu Steve, Ahuka Mundeke |
author_facet | Alain, Chabo Byaene Antoine, Lufimbo Katawandja Bizette, Bizeti Nsangu Dahlia, Pambu Dophie, Tshibuela Beya Jérémie, Muwonga Masidi Donatien, Kayembe Nzongola-Nkasu Steve, Ahuka Mundeke |
author_sort | Alain, Chabo Byaene |
collection | PubMed |
description | INTRODUCTION: Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the respiratory route. Thus, we hypothesize that the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The objective of this study was to compare the seroprevalence of PVB19 between asymptomatic HIV-positive and HIV-negative blood donors. METHODS: A random sample of 360 eligible blood donors were firstly examined for HIV antibodies by using ELISA automaton and so were categorized as HIV-positive donors and HIV-negative donors. Then the two categories of donors were examined for PVB19 IgG and IgM by using ELISA kits. The seroprevalence of PVB19 in HIV-positive donors was compared to that of HIV-negative donors by using chi-square test or Fisher's exact test. All statistical analyzes were performed with SPSS 21. RESULTS: The prevalences of PVB19 IgG and IgM in HIV-positive blood donors were 92.1% (35 of 38) and 44.7% (17 of 38), respectively and those in control group were 89.1% (287 of 322) and 46.3% (149 of 322), respectively. But for both IgG and IgM the difference was not statistically significant (p > 0.05). CONCLUSION: This research confirms our hypothesis: the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. |
format | Online Article Text |
id | pubmed-7255965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-72559652020-06-09 The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa Alain, Chabo Byaene Antoine, Lufimbo Katawandja Bizette, Bizeti Nsangu Dahlia, Pambu Dophie, Tshibuela Beya Jérémie, Muwonga Masidi Donatien, Kayembe Nzongola-Nkasu Steve, Ahuka Mundeke Pan Afr Med J Research INTRODUCTION: Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the respiratory route. Thus, we hypothesize that the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The objective of this study was to compare the seroprevalence of PVB19 between asymptomatic HIV-positive and HIV-negative blood donors. METHODS: A random sample of 360 eligible blood donors were firstly examined for HIV antibodies by using ELISA automaton and so were categorized as HIV-positive donors and HIV-negative donors. Then the two categories of donors were examined for PVB19 IgG and IgM by using ELISA kits. The seroprevalence of PVB19 in HIV-positive donors was compared to that of HIV-negative donors by using chi-square test or Fisher's exact test. All statistical analyzes were performed with SPSS 21. RESULTS: The prevalences of PVB19 IgG and IgM in HIV-positive blood donors were 92.1% (35 of 38) and 44.7% (17 of 38), respectively and those in control group were 89.1% (287 of 322) and 46.3% (149 of 322), respectively. But for both IgG and IgM the difference was not statistically significant (p > 0.05). CONCLUSION: This research confirms our hypothesis: the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The African Field Epidemiology Network 2020-03-10 /pmc/articles/PMC7255965/ /pubmed/32523647 http://dx.doi.org/10.11604/pamj.2020.35.69.21018 Text en © Chabo Byaene Alain et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Alain, Chabo Byaene Antoine, Lufimbo Katawandja Bizette, Bizeti Nsangu Dahlia, Pambu Dophie, Tshibuela Beya Jérémie, Muwonga Masidi Donatien, Kayembe Nzongola-Nkasu Steve, Ahuka Mundeke The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa |
title | The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa |
title_full | The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa |
title_fullStr | The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa |
title_full_unstemmed | The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa |
title_short | The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa |
title_sort | human parvovirus b19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the blood transfusion national center in kinshasa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255965/ https://www.ncbi.nlm.nih.gov/pubmed/32523647 http://dx.doi.org/10.11604/pamj.2020.35.69.21018 |
work_keys_str_mv | AT alainchabobyaene thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT antoinelufimbokatawandja thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT bizettebizetinsangu thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT dahliapambu thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT dophietshibuelabeya thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT jeremiemuwongamasidi thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT donatienkayembenzongolankasu thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT steveahukamundeke thehumanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT alainchabobyaene humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT antoinelufimbokatawandja humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT bizettebizetinsangu humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT dahliapambu humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT dophietshibuelabeya humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT jeremiemuwongamasidi humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT donatienkayembenzongolankasu humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa AT steveahukamundeke humanparvovirusb19humanimmunodeficiencyviruscoinfectioninhealthyeligiblevoluntaryblooddonorsatthebloodtransfusionnationalcenterinkinshasa |